This study is NOT currently recruiting participants.
Number
20-I-0123
Sponsoring Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Recruitment Detail
Type: No longer recruiting/follow-up only Gender: Male & Female Min Age: 18 Years Max Age: 120 Years
Referral Letter Required
No
Population Exclusion(s)
Children
Keywords
Coronavirus; SARS-CoV-2; Medical Sequelae; Antibody and Cell-mediated Immune Responses; Protective Immunity; Natural History
Recruitment Keyword(s)
None
Condition(s)
COVID-19
Investigational Drug(s)
Investigational Device(s)
Intervention(s)
Supporting Site
National Institute of Allergy and Infectious Diseases
COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract. Some people who get COVID-19 have only mild symptoms. But for others, infection leads to pneumonia, respiratory failure, and, in some cases, death. Researchers want to learn more about any effects that may persist after people recover from COVID-19.
Objective:
To learn about any long-term medical problems that people who have recovered from COVID-19 might have, and whether they develop an immune response to SARS-CoV-2 that provides protection against reinfection.
Eligibility:
People age 18 and older who have recovered from documented COVID-19 or were in close contact with someone who had COVID-19 but did not get the infection
Design:
Participants will be screened over 2 visits. During visit 1, they will answer questions about any symptoms they are having and will be tested for SARS-CoV-2 infection which will involve a nasal swab sample or other FDA approved test. If the test is negative, they will proceed to the second visit, which will include:
Physical examination
Medical history
Mental health interview (which may be recorded if the participant agrees)
Chest x-ray (for recovered COVID-19 participants only)
Blood and urine tests
Pregnancy test (if needed)
Lung function test (for recovered COVID-19 participants only)
6-minute walk test (for recovered COVID-19 participants only)
Questionnaires about their general and mental health
Leukapheresis to collect white blood cells (optional).
Participants will be put into 1 of 2 groups: the COVID-19 group or the close contact group.
Participants will have study visits every 6 months for 3 years. They will repeat some of the screening tests. Participants in the COVID-19 group may have visits more often if they develop symptoms that suggest re-infection with SARS-CoV-2.
--Back to Top--
INCLUSION CRITERIA: In order to be eligible to participate in this study, all individuals must meet all of the following criteria: 1) Stated willingness to comply with all study procedures and availability for the duration of the study 2) Age 18 years or older. 3) Ability of participant to understand and the willingness to sign a written informed consent document. 4) Hemoglobin of 9.0 gm/dl or higher 5) Willingness to give consent for the storage of blood samples for research. 6) Have a physician or clinic outside NIH to manage underlying medical conditions or agreeing to establish care with an outside physician or clinic for any medical conditions requiring treatment that may be diagnosed as a result of protocol participation. COVID-19 Survivor Group 1) Documented prior COVID-19 as evidenced by: a) detection of SARS-CoV-2 RNA or antigen in nasopharyngeal swab, sputum or other sample source with EUA/approval from the FDA; or b) a positive antibody test using an assay that has received emergency use authorization (EUA) from the Food and Drug Administration (FDA) and a history clinical manifestation compatible with COVID-19. 2) Greater than 6 weeks since onset of COVID-19 symptoms and no fever for at least 1 week. For individuals with asymptomatic infection, screening will not occur until at least 4 weeks after the last positive SARS-CoV-2 PCR or antigen test. COVID-19 Close Contact 1) Living in the same household as a COVID-19 survivor during the time of illness or, being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time or having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on). 2) No diagnosis of COVID-19 or current symptoms suggestive of COVID-19 EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Current abuse of alcohol or other drugs that, in the judgement of the Principal Investigator (PI) could interfere with patient compliance. 2. Inability to travel to the NIH Clinical Center for study visits 3. Any medical or mental health condition that, in the judgement of the PI, would make the volunteer unable to participate in the study. 4. Positive SARS-CoV-2 PCR at screening visit 5. Positive test for antibodies to SARS-CoV-2 nucleocapsid protein at the screening visit (control group only). 6. History of any of the following in the past 14 days: fever > 38.2 degrees Celsius; new or worsening respiratory symptoms (e.g. cough, dyspnea). 7. Pregnancy
In order to be eligible to participate in this study, all individuals must meet all of the following criteria:
1) Stated willingness to comply with all study procedures and availability for the duration of the study
2) Age 18 years or older.
3) Ability of participant to understand and the willingness to sign a written informed consent document.
4) Hemoglobin of 9.0 gm/dl or higher
5) Willingness to give consent for the storage of blood samples for research.
6) Have a physician or clinic outside NIH to manage underlying medical conditions or agreeing to establish care with an outside physician or clinic for any medical conditions requiring treatment that may be diagnosed as a result of protocol participation.
COVID-19 Survivor Group
1) Documented prior COVID-19 as evidenced by:
a) detection of SARS-CoV-2 RNA or antigen in nasopharyngeal swab, sputum or other sample source with EUA/approval from the FDA; or
b) a positive antibody test using an assay that has received emergency use authorization (EUA) from the Food and Drug Administration (FDA) and a history clinical manifestation compatible with COVID-19.
2) Greater than 6 weeks since onset of COVID-19 symptoms and no fever for at least 1 week. For individuals with asymptomatic infection, screening will not occur until at least 4 weeks after the last positive SARS-CoV-2 PCR or antigen test.
COVID-19 Close Contact
1) Living in the same household as a COVID-19 survivor during the time of illness or, being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time or having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on).
2) No diagnosis of COVID-19 or current symptoms suggestive of COVID-19
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
1. Current abuse of alcohol or other drugs that, in the judgement of the Principal Investigator (PI) could interfere with patient compliance.
2. Inability to travel to the NIH Clinical Center for study visits
3. Any medical or mental health condition that, in the judgement of the PI, would make the volunteer unable to participate in the study.
4. Positive SARS-CoV-2 PCR at screening visit
5. Positive test for antibodies to SARS-CoV-2 nucleocapsid protein at the screening visit (control group only).
6. History of any of the following in the past 14 days: fever > 38.2 degrees Celsius; new or worsening respiratory symptoms (e.g. cough, dyspnea).
7. Pregnancy
Principal Investigator
Referral Contact
For more information: